Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 10/20 | 0.45 |
| ▸ | CNR1 | P21554 | 9/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5554421 | 0.81 | PTGS2 (0.50) | CNR2CNR1PTGS2PTGS1 | |
| SCHEMBL5554423 | 0.81 | PTGS2 (0.50) | CNR2CNR1PTGS2PTGS1 | |
| SCHEMBL5547111 | 0.81 | PTGS2 (0.50) | CNR2CNR1PTGS2PTGS1 | |
| SCHEMBL6024947 | 0.80 | PTGS1 (0.66) | CNR2CNR1TP53CYP3A4HPGD | |
| SCHEMBL5554413 | 0.80 | PTGS2 (0.51) | PTGS2PTGS1 | |
| SCHEMBL5553785 | 0.80 | PTGS2 (0.51) | PTGS2PTGS1 | |
| SCHEMBL5553789 | 0.80 | PTGS2 (0.51) | PTGS2PTGS1 | |
| SCHEMBL5545939 | 0.80 | PTGS2 (0.65) | MTORPTGS2PTGS1 | |
| SCHEMBL5549754 | 0.80 | PTGS2 (0.65) | MTORPTGS2PTGS1 | |
| SCHEMBL5545907 | 0.80 | PTGS2 (0.65) | MTORPTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070293542-A1 | Selective Cox-2 Inhibitors | IRONWOOD PHARMACEUTICALS, INC. | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293542-A1 | Selective Cox-2 Inhibitors | PTGS2, FAAH2, PTGES2 | CNR2 12/4885CNR1 37/4885TP53 4773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.